Profile data is unavailable for this security.
About the company
Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. It has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.
- Revenue in INR (TTM)6.04bn
- Net income in INR-72.40m
- Incorporated1984
- Employees1.29k
- LocationPanacea Biotec LtdB-1 Extn / G-3Mathura Road, Mohan Co-opIndlEstateNEW DELHI 110044IndiaIND
- Phone+91 1 141679000
- Fax+91 1 141679075
- Websitehttps://www.panaceabiotec.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ngl Fine Chem Ltd | 4.47bn | 353.73m | 14.02bn | 456.00 | 39.65 | -- | 26.35 | 3.14 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Beta Drugs Ltd | 3.86bn | 464.68m | 14.73bn | 399.00 | 20.93 | 6.67 | 24.05 | 3.82 | 69.72 | 65.19 | 509.33 | 218.94 | 0.986 | 3.64 | 3.48 | 9,665,303.00 | 11.88 | 15.08 | 16.29 | 21.53 | 39.79 | 40.30 | 12.05 | 12.72 | 2.45 | 5.13 | 0.3974 | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| Windlas Biotech Ltd | 8.30bn | 673.21m | 17.64bn | 1.35k | 26.33 | 3.28 | 18.07 | 2.12 | 31.79 | 31.79 | 392.02 | 254.82 | 1.06 | 6.73 | 4.32 | 6,167,994.00 | 8.62 | 8.65 | 13.24 | 11.81 | 38.24 | 34.09 | 8.11 | 7.70 | 1.80 | 15.42 | 0.0552 | 18.33 | 20.43 | 18.24 | 4.82 | 30.34 | 27.99 | -- |
| Amrutanjan Health Care Ltd | 4.88bn | 569.03m | 18.20bn | 631.00 | 31.99 | -- | 28.78 | 3.73 | 19.68 | 19.68 | 168.85 | -- | -- | -- | -- | 7,736,897.00 | -- | 15.84 | -- | 19.67 | 50.87 | 52.17 | 11.66 | 13.26 | -- | 319.69 | -- | 19.82 | 7.26 | 11.56 | 13.03 | 15.17 | 69.46 | 26.76 |
| Bliss GVS Pharma Ltd | 8.60bn | 1.10bn | 19.65bn | 966.00 | 18.02 | 1.73 | 13.33 | 2.28 | 10.31 | 10.31 | 80.97 | 107.18 | 0.6414 | 3.38 | 1.87 | 8,905,504.00 | 8.60 | 6.04 | 10.41 | 7.54 | 50.76 | 46.33 | 13.42 | 9.45 | 3.86 | 8.37 | 0.043 | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Indoco Remedies Ltd | 17.23bn | -1.10bn | 20.48bn | 6.05k | -- | 2.09 | 493.54 | 1.19 | -12.40 | -12.40 | 198.07 | 106.21 | 0.7037 | 1.24 | 4.13 | 2,847,991.00 | -4.71 | 4.84 | -7.40 | 6.87 | 70.97 | 65.70 | -6.69 | 5.16 | 0.6666 | -0.5619 | 0.5062 | 17.11 | -8.38 | 8.51 | -174.89 | -- | 43.53 | -7.79 |
| Morepen Laboratories Ltd | 17.55bn | 986.27m | 20.81bn | 1.81k | 21.04 | 1.74 | 14.74 | 1.19 | 1.80 | 1.80 | 32.16 | 21.83 | 1.06 | 4.24 | 6.12 | 9,677,225.00 | 6.03 | 8.14 | 8.20 | 12.81 | 33.02 | 31.83 | 5.67 | 5.91 | 1.65 | 6.43 | 0.1169 | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 21.70bn | 1.16bn | 22.50bn | 2.89k | 19.41 | 1.28 | 11.66 | 1.04 | 3.95 | 3.95 | 73.97 | 59.66 | 0.9278 | 3.77 | 4.39 | 7,507,091.00 | 4.95 | 10.26 | 6.48 | 13.42 | 34.01 | 32.57 | 5.34 | 9.33 | 1.32 | 9.37 | 0.0832 | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Panacea Biotec Ltd | 6.04bn | -72.40m | 22.79bn | 1.29k | -- | 2.76 | 86.84 | 3.77 | -1.18 | -1.18 | 98.44 | 134.92 | 0.4836 | 1.38 | 8.67 | 4,681,039.00 | -0.6085 | 13.08 | -0.8291 | 19.61 | 58.47 | 48.06 | -1.26 | 30.99 | 0.9785 | -14.33 | 0.0271 | 0.00 | -0.0132 | 0.5466 | -613.56 | -- | 48.74 | -- |
| Solara Active Pharma Sciences Ltd | 12.06bn | 64.10m | 23.37bn | 1.78k | 438.71 | 2.02 | 22.62 | 1.94 | 1.20 | 1.20 | 325.96 | 261.13 | 0.5263 | 1.68 | 3.32 | 6,794,423.00 | 0.2797 | -3.27 | 0.4821 | -5.35 | 54.11 | 39.95 | 0.5315 | -6.17 | 0.4929 | 0.9751 | 0.3394 | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| Hikal Ltd | 16.99bn | 101.00m | 23.54bn | 2.06k | 232.32 | 1.97 | 14.56 | 1.39 | 0.8216 | 0.8216 | 137.81 | 96.86 | 0.7065 | 2.01 | 4.59 | 8,239,573.00 | 0.42 | 4.78 | 0.6016 | 7.00 | 55.49 | 48.00 | 0.5945 | 5.71 | 0.5418 | 1.11 | 0.3639 | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| SMS Pharmaceuticals Ltd | 8.60bn | 843.60m | 30.01bn | 1.47k | 33.08 | 4.11 | 25.41 | 3.49 | 9.69 | 9.69 | 98.93 | 77.88 | 0.7134 | 1.82 | 3.96 | 5,850,513.00 | 6.72 | 5.58 | 9.76 | 7.66 | 33.05 | 33.78 | 9.42 | 8.05 | 0.916 | 5.98 | 0.3078 | 5.72 | 10.36 | 13.70 | 38.75 | 16.97 | 23.62 | 9.86 |
| Unichem Laboratories Ltd | 22.26bn | 884.60m | 30.26bn | 3.33k | 34.34 | 1.24 | 14.28 | 1.36 | 12.51 | 12.51 | 315.90 | 345.83 | 0.6483 | 1.07 | 3.16 | 6,690,202.00 | 2.58 | -0.5598 | 3.52 | -0.6977 | 56.35 | 55.09 | 3.97 | -1.18 | 1.03 | 4.98 | 0.1709 | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| Gufic BioSciences Ltd | 8.74bn | 569.19m | 30.90bn | 1.99k | 54.26 | 4.90 | 36.41 | 3.54 | 5.68 | 5.68 | 87.10 | 62.94 | 0.7354 | 1.87 | 2.75 | 4,394,322.00 | 4.79 | 10.27 | 7.34 | 16.11 | 55.47 | 46.41 | 6.52 | 10.48 | 1.06 | 3.13 | 0.3691 | 1.31 | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
Data as of Feb 06 2026. Currency figures normalised to Panacea Biotec Ltd's reporting currency: Indian Rupee INR
0.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 74.94k | 0.12% |
| Dimensional Fund Advisors Ltd.as of 31 May 2025 | 4.03k | 0.01% |
| American Century Investment Management, Inc.as of 08 Jan 2026 | 883.00 | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 482.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Dec 2025 | 210.00 | 0.00% |
| DFA Australia Ltd.as of 30 Nov 2025 | 170.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 15 Jan 2026Source: FactSet Research Systems Inc.
